Detalles de la búsqueda
1.
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 20(1): 105-115.e14, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32950748
2.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Gastroenterology
; 158(3): 537-549.e10, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31493397
3.
CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome.
Br J Clin Pharmacol
; 80(6): 1388-98, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26264702
4.
Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
Clin Pharmacokinet
; 62(10): 1479-1491, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610533
5.
Robust central reduction of amyloid-ß in humans with an orally available, non-peptidic ß-secretase inhibitor.
J Neurosci
; 31(46): 16507-16, 2011 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-22090477
6.
The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Drug Metab Dispos
; 40(10): 1945-52, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22789530
7.
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
Alzheimers Dement
; 8(4): 261-71, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22672770
8.
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
Ann Neurol
; 66(1): 48-54, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19360898
9.
Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
J Clin Pharmacol
; 58(11): 1489-1500, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29878382
10.
Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.
J Clin Pharmacol
; 55(7): 757-67, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25651523
11.
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.
Pharmacol Res Perspect
; 3(5): e00179, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26516590
12.
A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.
J Cardiovasc Pharmacol Ther
; 20(5): 483-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25736283
13.
Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model.
Neoplasia
; 4(5): 449-63, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-12192604
14.
Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys.
Transplantation
; 75(12): 2106-13, 2003 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-12829920
15.
Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants.
J Cardiovasc Pharmacol Ther
; 19(3): 283-9, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24271137
16.
Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.
J Pharm Pharmacol
; 66(11): 1576-85, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24961753
17.
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid ß monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.
Clin Neuropharmacol
; 35(1): 25-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22134132
18.
Sustained levels of antibodies against Aß in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.
Exp Neurol
; 238(1): 38-43, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22892246
19.
Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.
J Clin Pharmacol
; 52(6): 904-13, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21724950
20.
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
Clin Neuropharmacol
; 33(2): 67-73, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20375655